Korea Comirnaty Post-marketing Surveillance

计划入组 12,000 人 · 首次发布于 2021 年 9 月 2 日

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

计划入组 344 人 · 首次发布于 2025 年 10 月 29 日

Drug Use Investigation of COMIRNATY Intramuscular Injection

计划入组 14,570 人 · 首次发布于 2021 年 3 月 24 日

LP-342

LP-922056

LP-08

Janssen LP

United States

AstraZeneca LP

United States

Covidien LP

United States

Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine Receives Regulatory Approval in Australia and New Zealand

FDA Approves Pfizer-BioNTech LP.8.1-Adapted COVID-19 Vaccine for High-Risk Populations

Pfizer and BioNTech Submit EMA Application for Updated COVID-19 Vaccine Targeting LP.8.1 Strain for 2025-2026 Season